Results 191 to 200 of about 209,106 (262)

Circulating tumor DNA in neoadjuvant therapy for solid tumors. [PDF]

Front Oncol
Huang X, Deng Y, Shen Y.
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non‐Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori, Tateaki Naito, Nobuko Konishi, Tetsuya Tsuji, Ikumi Takashima, Ryotaro Ide, Masakazu Fujiwara, Atsuki Yamamoto, Yusuke Takagi, Mizue Ogi, Shinya Uematsu, Hiroshi Kitagawa, Koichi Takayama   +12 more
wiley   +1 more source

Association of HRD Score With Efficacy of Neoadjuvant Short-Course Radiotherapy Plus Sequential Chemoimmunotherapy in pMMR Locally Advanced Rectal Cancer. [PDF]

Cancer Rep (Hoboken)
Ran X, Xiao H, Zhou P, He J, Si M, Chen X, Su X, Chen Z, Du J, Dai X, Yang X, Shen H, He Z, Li F, Li M, Chen C.   +15 more
europepmc   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework. [PDF]

Front Oncol
Yıldız İ, Şenocak Taşçı E, Ağaoğlu F.   +2 more
europepmc   +1 more source

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source